Rocket Pharmaceuticals (RCKT) Share-based Compensation (2016 - 2025)
Historic Share-based Compensation for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $9.8 million.
- Rocket Pharmaceuticals' Share-based Compensation fell 1323.79% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.0 million, marking a year-over-year decrease of 170.01%. This contributed to the annual value of $43.9 million for FY2024, which is 1145.51% up from last year.
- Latest data reveals that Rocket Pharmaceuticals reported Share-based Compensation of $9.8 million as of Q3 2025, which was down 1323.79% from $10.9 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Share-based Compensation registered a high of $11.3 million during Q2 2024, and its lowest value of $6.3 million during Q1 2022.
- For the 5-year period, Rocket Pharmaceuticals' Share-based Compensation averaged around $9.2 million, with its median value being $9.8 million (2025).
- In the last 5 years, Rocket Pharmaceuticals' Share-based Compensation surged by 9944.46% in 2021 and then plummeted by 2063.29% in 2022.
- Over the past 5 years, Rocket Pharmaceuticals' Share-based Compensation (Quarter) stood at $7.0 million in 2021, then skyrocketed by 37.74% to $9.7 million in 2022, then rose by 2.45% to $9.9 million in 2023, then increased by 11.66% to $11.1 million in 2024, then decreased by 11.99% to $9.8 million in 2025.
- Its last three reported values are $9.8 million in Q3 2025, $10.9 million for Q2 2025, and $10.3 million during Q1 2025.